Second malignancies after Ewing tumor treatment in 690 patients from a cooperative German/Austrian/Dutch study

Background Ewing tumor treatment involves high cumulative doses of alkylating agents and topoisomerase inhibitors, drugs capable of inducing second cancers We analyzed the second cancer risk in a large cohort of consistently treated patients Patients and methods Six hundred ninety Ewing tumor patients were treated between 1992 and 1999 with local therapy and vincristine, doxorubicin, ifosfamide and/or cyclophosphamide, and antinomycin D, with or without etoposide as a randomized question Second cancer incidences were estimated by competing risk analyses, standardized incidence ratios (SIR) in... Mehr ...